STXS icon

Stereotaxis

2.19 USD
-0.10
4.37%
At close Feb 21, 4:00 PM EST
After hours
2.18
-0.01
0.46%
1 day
-4.37%
5 days
-3.52%
1 month
0.92%
3 months
6.83%
6 months
-0.90%
Year to date
-4.37%
1 year
-30.70%
5 years
-50.23%
10 years
-1.35%
0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2,469% more call options, than puts

Call options by funds: $822K | Put options by funds: $32K

185% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 13

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

14% more capital invested

Capital invested by funds: $82.4M [Q3] → $93.8M (+$11.4M) [Q4]

1% more funds holding

Funds holding: 83 [Q3] → 84 (+1) [Q4]

0.86% more ownership

Funds ownership: 47.72% [Q3] → 48.58% (+0.86%) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for STXS.

Financial journalist opinion

Based on 5 articles about STXS published over the past 30 days

Positive
Seeking Alpha
1 week ago
Stock Market Sleeps On Stereotaxis MAGiC CE Mark
Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. This will further drive recurring revenue and stock momentum. GenesisX's first order was announced. A successful practice will be pivotal for future orders which should begin after the commercial launch at the EHRA Congress in March/April.
Stock Market Sleeps On Stereotaxis MAGiC CE Mark
Positive
Zacks Investment Research
2 weeks ago
STXS Stock Gains Following the First Order for its GenesisX
Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.
STXS Stock Gains Following the First Order for its GenesisX
Neutral
GlobeNewsWire
2 weeks ago
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company's results and corporate developments.
Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Neutral
GlobeNewsWire
3 weeks ago
Stereotaxis Announces First GenesisX Robotic System Order
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
Stereotaxis Announces First GenesisX Robotic System Order
Neutral
GlobeNewsWire
3 weeks ago
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company's commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
Neutral
GlobeNewsWire
1 month ago
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.
Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
Positive
Zacks Investment Research
2 months ago
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Neutral
GlobeNewsWire
2 months ago
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA).
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA
Neutral
GlobeNewsWire
2 months ago
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL.
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Positive
Seeking Alpha
2 months ago
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
Charts implemented using Lightweight Charts™